<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871750</url>
  </required_header>
  <id_info>
    <org_study_id>SYW_01</org_study_id>
    <nct_id>NCT04871750</nct_id>
  </id_info>
  <brief_title>Effects of Dietary Soy Protein on Facial Wrinkles in Postmenopausal Women</brief_title>
  <official_title>Prospective, Randomized Controlled Study on the Effects of Dietary Soy Protein on Facial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Integrative Skin Science and Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United Soybean Board</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Integrative Skin Science and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Soy and soy-derived products are the primary dietary sources of isoflavones, particularly&#xD;
      daidzein and genistein, for humans. Isoflavones are noted to have several effects on the skin&#xD;
      including proliferation of keratinocytes resulting in epidermal thickening and increasing&#xD;
      collagen and moisture content of the skin. Previous work has shown that the ingestion of an&#xD;
      oral supplement containing soy isoflavones as a component led to a clinically measurable&#xD;
      improvement in wrinkle depth after 14 weeks of supplementation.&#xD;
&#xD;
      Ingestion of soy-based products has been shown to shift the Bifidobacteria and Lactobacilli&#xD;
      among the gut microbiota and modulate the ratio of Firmicutes to Bacteroidetes. Many studies&#xD;
      have shown that short-chain fatty acids result from beneficial shifts in the gut microbiome&#xD;
      and may influence the inflammatory state of the skin.&#xD;
&#xD;
      Therefore, the study aims to investigate whether soy-derived isoflavone can reduce wrinkles&#xD;
      and alter both gut microbiome and short-chain fatty acids.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Healthy postmenopausal women aged 50 to 70, with Fitzpatrick skin type I or II.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Facial wrinkles</measure>
    <time_frame>week 24</time_frame>
    <description>Wrinkle severity score measured by Facial Image Analysis System</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procollagen I expression</measure>
    <time_frame>24</time_frame>
    <description>Assess with biopsy (optional participation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pigment intensity score</measure>
    <time_frame>week 24</time_frame>
    <description>Measured by the 3D Clarity Pro® Facial Modeling and Analysis System (Brigh-Tex BioPhotonics, San Jose, CA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood levels of soy isoflavones and metabolites</measure>
    <time_frame>week 24</time_frame>
    <description>Blood samples will be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiome</measure>
    <time_frame>week 24</time_frame>
    <description>Evaluate changes in the gut microbiome (Bifidobacteria and Lactobacilli, ratio of Firmicutes to Bacteroidetes) through stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipidome</measure>
    <time_frame>week 24</time_frame>
    <description>Assess changes in butyrate, propionate, and acetate levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial wrinkles</measure>
    <time_frame>week 8</time_frame>
    <description>Wrinkle score measured by Facial Image Analysis System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial wrinkles</measure>
    <time_frame>week 16</time_frame>
    <description>Wrinkle score measured by Facial Image Analysis System</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Photoaging</condition>
  <arm_group>
    <arm_group_label>Soy protein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 g powder/day, contains 50 mg of isoflavones</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Casein protein</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 g powder/day, no isoflavones</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soy protein</intervention_name>
    <description>Daily consumption for 24 weeks</description>
    <arm_group_label>Soy protein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Casein protein</intervention_name>
    <description>Daily consumption for 24 weeks</description>
    <arm_group_label>Casein protein</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal females, 50 to 70 years of age&#xD;
&#xD;
          -  Fitzpatrick skin type I or II, based on skin melanin content&#xD;
&#xD;
          -  BMI 18.5-35 kg/m2&#xD;
&#xD;
          -  Must be willing to comply with all protocol requirements&#xD;
&#xD;
          -  Must be willing to have flash photo facial images taken with the imaging systems&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any systemic or antibiotics (injected or oral) within 6 months of starting study&#xD;
&#xD;
          -  Any topical antibiotic or benzoyl peroxide within 1 month of starting study or any&#xD;
             subject unwilling to refrain from washout of topical antibacterial or benzoyl peroxide&#xD;
             ingredient.&#xD;
&#xD;
          -  Allergic to soy and milk products&#xD;
&#xD;
          -  Fruit consumption &gt; 2 cups/day&#xD;
&#xD;
          -  Vegetable consumption &gt; 3 cups/day for females&#xD;
&#xD;
          -  Fruit juice consumption &gt; 1 cup/day&#xD;
&#xD;
          -  Coffee consumption &gt; 1 cup per day&#xD;
&#xD;
          -  Alcohol consumption ≥ 3 servings per week (1 serving = 1 bottle of beer, ½ glass of&#xD;
             wine, or 1 shot of hard liquor)&#xD;
&#xD;
          -  Self-reported malabsorption&#xD;
&#xD;
          -  Any oral probiotic or prebiotic supplementation within past 1 month at the discretion&#xD;
             of the investigator. Probiotic and prebiotic containing foods are NOT considered an&#xD;
             exclusion.&#xD;
&#xD;
          -  Subjects must have no history of malignancy or cancer or diagnosis of gastrointestinal&#xD;
             inflammatory diseases, no history or diagnosis of epilepsy, no history or diagnosis of&#xD;
             immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus,&#xD;
             rheumatoid arthritis)&#xD;
&#xD;
          -  Has a condition or is on medication the investigator and/or designee believe could&#xD;
             jeopardize the safety of the subject, interfere with the evaluation, or confound the&#xD;
             interpretation of the study results&#xD;
&#xD;
          -  Is participating in a concurrent intervention based clinical research study&#xD;
&#xD;
          -  Commencement of a new diet (such as the ketogenic diet) or supplements within the 1&#xD;
             month prior to initiating participation, at the discretion of the investigator.&#xD;
&#xD;
          -  Use of medications that alter blood lipids, such as statins and anti-hyperlipidemic&#xD;
             medications&#xD;
&#xD;
          -  Is participating in or has participated in a intervention based facial study at this&#xD;
             or any other facility in the past 2 weeks. Participation in survey-based studies are&#xD;
             approved at the discretion of the investigator.&#xD;
&#xD;
          -  Has a skin disease on face that will interfere with image collection and assessment in&#xD;
             the opinion of the investigator&#xD;
&#xD;
          -  Persons unwilling to avoid the following during the 4 weeks prior and during the&#xD;
             duration of the study: self-tanning, spa tanning, sun tanning, or artificial tanning.&#xD;
&#xD;
          -  Planned vacation to sunny destination with the intention of sun tanning during the&#xD;
             duration of the study.&#xD;
&#xD;
          -  Persons who regularly undergo sauna treatments (dry or wet) or who swim daily. Known&#xD;
             allergy or irritation to the supplement or facial products utilized in the study&#xD;
&#xD;
          -  Current tobacco smokers, OR those that have smoked tobacco over the past year, OR a 5&#xD;
             year-pack year history of smoking tobacco&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Adults unable to consent&#xD;
&#xD;
          -  Vegans and vegetarians&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Raja K Sivamani, MD</last_name>
    <phone>(916) 524-1216</phone>
    <email>raja.sivamani@integrativeskinresearch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vivien W Fam, RD</last_name>
    <phone>(530) 760-5968</phone>
    <email>vivien@integrativeskinresearch.com</email>
  </overall_contact_backup>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Facial Wrinkles</keyword>
  <keyword>Soy-derived isoflavone</keyword>
  <keyword>Short-chain fatty acids</keyword>
  <keyword>Gut microbiome</keyword>
  <keyword>Dermatology</keyword>
  <keyword>Supplementation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caseins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

